Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Group 1 - Lineage Cell (LCTX) reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of$0.04, representing an earnings surprise of 50% [1] - The company posted revenues of $3.78 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 222.99$1.25 million in the same quarter last year [2] - Over the last four quarters, Lineage Cell has surpassed consensus EPS estimates three times and topped revenue estimates two times [2] Group 2 - The stock has underperformed, losing about 16.2% since the beginning of the year, while the S&P 500 gained 25.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of$2.02 million, and for the current fiscal year, it is -$0.15 on revenues of$6.06 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]